ClinicalTrials.gg
TerminatedNCT03743246Updated Aug 15, 2024Results posted

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

A Phase 1/2 interventional study of JCAR017 and Lymphodepleting in Precursor Cell Lymphoblastic Leukemia-Lymphoma and Lymphoma, Non-Hodgkin, sponsored by Celgene. Terminated at 19 sites in 6 countries. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Absence of significant therapeutic benefit over existing therapies

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
Up to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Bristol-Myers Squibb.

Started
2018
the only one that year
Phase 1/2
3 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb, this one is the only one that started in 2018, is one of 3 in phase 1/2, and was the 11th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

None of the 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb is open now. The open studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, anywhere →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: Up to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Bristol-Myers Squibb as a file.
02

Study summary

This is a Phase 1/2, open-label, single arm, multicohort study to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.

Phase 1 will identify a recommended Phase 2 dose (RP2D). Phase 2 will evaluate the efficacy of JCAR017 RP2D in the following three disease cohorts: Cohort 1 (r/r B-ALL), Cohort 2 (MRD+ B-ALL) and Cohort 3 (r/r B-NHL, [DLBCL, BL, or PMBCL]). A Simon's Optimal two-stage study design will be applied to Cohort 1 and 2 in Phase 2.

Read the detailed description

This is a Phase 1/2, open-label, single arm, multicohort study incorporating Simon's Optimal two-stage design to evaluate the safety and efficacy of JCAR017 in pediatric subjects aged ≤ 25 years with CD19+ r/r B-ALL and B-NHL.

In the Phase 1, up to 5 dose levels will be of JCAR017 will be evaluated. Enrollment will commence in pediatric subjects with r/r B-ALL at Dose Level 1 (DL1) of 0.05x10\^6 CAR+ T cells/kg (maximum DL1 of 5x10\^6 JCAR017 CAR+ T cells [non-weight adjusted]). If this dose is confirmed to be safe and tolerable, additional subjects will be enrolled at higher dose(s) up to 0.75 x10\^6 CAR+ T cells/kg (maximum of 75x10\^6 JCAR017 CAR+ T cells [non-weight adjusted]) with the aim to identify the RP2D. Dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. A Safety Review Committee (SRC) will recommend the Phase 2 dose (defined as RP2D) based on an integrated assessment of the safety, PK and preliminary efficacy information from at least 10 pediatric subjects treated at the RP2D.

In Phase 2, a minimum of 71 additional subjects (\< 18 years of age) will be enrolled into one of the 3 cohorts listed below. The sample size for Cohorts 1 and 2 is calculated according to Simon's Optimal two-stage design. The 10 or more pediatric subjects treated at the RP2D in Phase 1 will form part of the sample size (ie, Cohort 1 and Cohort 2). Therefore, the protocol intends to treat 81 primary endpoint evaluable pediatric subjects in Phase 2, if warranted by the evaluation of results at the completion of the first stage of the study in each cohort.

  • Cohort 1 (r/r B-ALL): 48 evaluable pediatric subjects (13 subjects in Stage 1 and 35 in Stage 2)
  • Cohort 2 (MRD+ B-ALL): 23 evaluable pediatric subjects (9 subjects in Stage 1 and 14 subjects in Stage 2)
  • Cohort 3 (r/r B-NHL [DLBCL, BL, or PMBCL]): 10 evaluable pediatric subjects. Due to the very low incidence rate and therefore expected low subject accrual, there is no formal sample size for this arm.

Up to 20 additional B-ALL subjects between 18 and 25 years of age may be enrolled in Phase 2.

Following treatment with JCAR017 subjects will then enter the post-treatment period for disease progression/relapse, safety, CAR T cell persistence, and survival up to 24 months after administration of JCAR017.

Efficacy will be assessed both locally and by an Independent Review Committee. Response assessments will be based on bone marrow and blood morphologic criteria, physical examination findings, along with laboratory assessments of cerebral spinal fluid (CSF) and bone marrow MRD (B-ALL only) assessments. B-NHL subjects will also have radiographic disease assessment by CT/MRI scans and tumor biopsies, if accessible.

Post-study follow-up for survival, relapse, long-term toxicity, and lentiviral vector safety will continue under a separate long-term follow-up protocol for up to 15 years after the JCAR017 infusion as per health authority regulatory guidelines.

An Independent Data Monitoring Committee will monitor the study conduct.

03

Conditions studied

  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Lymphoma, Non-Hodgkin

Keywords

  • Pediatric
  • JCAR017
  • CAR-T
  • CART
  • CD19
  • ALL
  • NHL
  • DLBCL
  • BL
  • PMBCL
  • Cell Therapy
  • LisoCell
  • Young Adults
  • Lymphoproliferative disorders
  • Immune system diseases
  • Leukemia
  • Lymphoma
  • lymphatic diseases
04

Who can participate

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Phase 1: Subject \< 18 years of age and weighs ≥ 6 kg at the time of signing the form (ICF)/informed assent form (IAF).

    Phase 2: Subject ≤ 25 years of age and weighs ≥ 6 kg at the time of signing the ICF/IAF.

  2. Subject (when applicable, parental/legal representative) must understand and voluntarily provide permission to the ICF/IAF prior to conducting any study-related assessments/procedures.
  3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  4. Investigator considers the subject is appropriate for adoptive T cell therapy.
  5. Evidence of CD19 expression via flow cytometry (peripheral blood or bone marrow) or immunohistochemistry (bone marrow )
  6. Subject has a score of ≥ 50 (subjects ≥ 16 years of age) or a Lansky score ≥ 50 (subjects \< 16 years of age).
  7. Diagnosis of B-cell ALL or B-cell NHL as defined below:

    Phase 1: Subjects with r/r B-ALL, defined as morphological evidence of disease in BM (5% or greater lymphoblast by morphology) and either of the following:

    • First or greater marrow relapse, or
    • Any marrow relapse after HSCT, or
    • Primary defined as not achieving a CR or a CRi after 2 or more separate induction regimens (or chemo-refractory as not achieving CR/CRi after 1 cycle of standard chemotherapy for relapsed leukemia), or
    • Ineligible for allogeneic HSCT Note: Subjects will be included regardless of MRD status.

    Phase 2: Subjects with one of the following:

    • Cohort 1: r/r B-ALL, defined as morphological evidence of disease in BM (5% or greater lymphoblast by morphology) and either:

      • First or greater marrow relapse, or
      • Any marrow relapse after allogeneic HSCT, or
      • Primary refractory defined as not achieving a CR or a CRi after 2 or more separate induction regimens (or chemo-refractory as not achieving CR/CRi after 1 cycle of standard chemotherapy for relapsed leukemia), or
      • Ineligible for allogeneic HSCT.
    • Cohort 2: MRD+ B-ALL, defined as:

      • \< 5% lymphoblasts by morphology with,
      • MRD detected by a validated assay at a frequency of 1 x10-4 or greater in BM cells. Subjects eligible for enrollment in Cohort 2 are those with MRD positive morphologic CR2 after re-induction when these subjects had previously experienced an early relapse (\< 36 months) after chemotherapy. Subjects who are in MRD+ morphologic CR3 and later, regardless of time to relapse in earlier lines, are also eligible. Subjects who are in morphologic relapse at screening (r/r B-ALL) and become MRD+ after bridging chemotherapy are also eligible for treatment in Cohort 2.
    • Cohort 3: r/r B-NHL (DLBCL, BL or PMBCL), defined as after 1 or more lines of chemotherapy and/or having failed HSCT or being ineligible for HSCT.

    Note: B-NHL subjects with secondary CNS lymphoma involvement are eligible however subject selection must consider clinical risk factors for severe neurological AEs and alternative treatment options. Subjects should only be enrolled if the Investigator considers the potential benefit outweighs the risk for the subject.

  8. Subjects with Philadelphia chromosome positive ALL are eligible if they are intolerant to or have failed one or more lines of tyrosine-kinase inhibitor (TKI) therapy or if TKI therapy is .
  9. Adequate organ function, defined as:

    • Adequate BM function to receive LD chemotherapy as assessed by the Investigator.
    • Subject with adequate renal function, which is defined as:

    Serum creatinine based on age/gender as described below. Subjects that do not meet the criteria but who have a or radioisotope (GFR) > 70 mL/min/1.73 m2 are eligible.• (ALT) ≤ 5 x (ULN) and total \< 2.0 mg/dL (or \< 3.0 mg/dL for subjects with Gilbert's syndrome or leukemic/lymphomatous infiltration of the liver).

    • Adequate pulmonary function, defined as ≤ Grade 1 dyspnea according to Common Toxicity Criteria for Adverse Events () and oxygen saturation (SaO2) ≥ 92% on room air.
    • Adequate cardiac function, defined as (LVEF) ≥ 40% as assessed by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) within 4 weeks prior to leukapheresis.
  10. Adequate vascular access for leukapheresis procedure.
  11. Participants must agree to use effective

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
  2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Subject has any condition that confounds the ability to interpret data from the study.
  4. Subject with a history of another primary that has not been in remission for at least 2 years prior to enrollment.
  5. Subjects who have received previous CD19-targeted therapy must have CD19-positive disease confirmed since completing the prior CD19-targeted therapy.
  6. Prior CAR T cell or other genetically-modified T cell therapy.
  7. Subject with a previous history of or active , , or (HIV) infection.
  8. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection (including tuberculosis) despite appropriate antibiotics or other treatment at the time of leukapheresis or JCAR017 infusion.
  9. Subject has presence of acute or chronic (GVHD).
  10. Subject with active disease requiring therapy.
  11. Subject has cardiac disorders ( version 4.03 Grade 3 or 4) within the past 6 months.
  12. Subject with a concomitant genetic syndrome, with the exception of Down's syndrome.
  13. Subject with active CNS disease and significant neurological deterioration. Subjects with CNS-2 or CNS-3 involvement are eligible provided they are asymptomatic and do not have significant neurological deterioration and, in the opinion of the study investigator, the CNS disease burden can be controlled until JCAR017 infusion.
  14. Subject with a history or presence of CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, cerebral edema, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
  15. Subject is pregnant or nursing.
  16. Subject has used the following:

    • Therapeutic doses of (defined as > 0.4 mg/kg maximum 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis or 72 hours prior to JCAR017 infusion. Physiologic replacement, topical, and inhaled steroids are permitted.
    • Low-dose chemotherapy (eg, vincristine, rituximab, cyclophosphamide ≤ 300 mg/m2) given after leukapheresis to maintain disease control must be stopped ≥ 7 days prior to LD chemotherapy.
    • Cytotoxic chemotherapeutic agents that are not considered lymphotoxic within 1 week prior to leukapheresis. Oral anticancer agents are allowed if at least 3 half-lives have elapsed prior to leukapheresis.
    • Lymphotoxic chemotherapeutic agents (eg, cyclophosphamide, ifosfamide, bendamustine) within 2 weeks prior to leukapheresis.
    • Experimental agents within 4 weeks prior to leukapheresis unless no response or PD is documented on the experimental therapy and at least 3 half-lives have elapsed prior to leukapheresis.
    • Immunosuppressive therapies within 4 weeks prior to leukapheresis and JCAR017 infusion (eg, calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as antitumor necrosis factor [TNF], anti-IL-6, or anti-IL-6R).
    • Donor lymphocyte infusions (DLI) within 6 weeks prior to JCAR017 infusion.
    • Radiation within 6 weeks prior to leukapheresis. Subjects must have PD in irradiated lesions or have additional non-irradiated lesions to be eligible. Radiation to a single lesion, if additional non-irradiated, are present, is allowed up to 2 weeks prior to leukapheresis.
    • HSCT within 90 days prior to leukapheresis.
  17. Tumor invasion of venous or arterial vessels (B-NHL subjects only).
  18. Deep Venous Thrombosis (DVT) or Pulmonary Embolism (PE) within 3 months prior to leukapheresis. Subjects with DVT or PE that occurred longer than 3 months prior to leukapheresis, who still require ongoing therapeutic levels of anti-coagulation therapy, are also excluded.
  19. Existence of CD19-negative clone(s) of leukemia cells
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Administration of JCAR017

    Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2

    Drug: JCAR017 · Drug: Lymphodepleting · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events up to 30 Days Post JCAR017 Infusion

    An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 30 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.

    Time frame: From first JCAR017 infusion (Day 1) to 30 days after JCAR017 infusion

  2. Number of Participants With Dose Limiting Toxicities

    A DLT was defined as: * Death not related to disease progression * Grade (Gr) 4 (Life-threatening) neurotoxicity * Gr 3 (Severe) neurotoxicity of greater than 7 days * Gr 3 neurotoxicity does not revert to baseline within 28 days of the start date of the Grade 3 event * Seizures of grade that do not resolve within 7 days * Gr 4 cytokine release syndrome (CRS) that does not resolve to Grade ≤ 3 within 3 days * Gr 3 CRS that does not resolve to Grade ≤ 2 within 7 days * Any increase in aspartate aminotransferase (AST) or ALT \> 3 × ULN and concurrent increase in total bilirubin \> 2 × ULN that is unrelated to CRS and has no other probable reason to explain the combination of increases * Any cardiac, dermatologic, gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic Gr 3 or 4 event not pre-existing or not due to the underlying malignancy * Any other Gr 3 or 4 event deemed unexpected by the Investigator and considered a DLT upon evaluation by the safety review committee

    Time frame: From first JCAR017 infusion (Day 1) to 28 days after JCAR017 infusion

  3. Concentration of JCAR017 in Peripheral Blood at Day 28 Post JCAR017 Infusion

    Concentration of JCAR017 in Peripheral Blood was assessed by droplet digital polymerase chain reaction.

    Time frame: At day 28 post JCAR017 infusion

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion

    An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater. The following scale for grading was used - Grade 3 = Severe, Grade 4 = Life-Threatening.

    Time frame: From first JCAR017 infusion (Day 1) to 90 days after JCAR017 infusion

  2. Number of Participants With Serious Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion

    Serious adverse events (SAE) are defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/ birth defect; constitutes an important medical event. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.

    Time frame: From first JCAR017 infusion (Day 1) to 90 days after JCAR017 infusion

  3. Change From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  4. Change From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils/Leukocytes; Eosinophils/Leukocytes; Lymphocytes/Leukocytes; Neutrophils/Leukocytes; Monocytes/Leukocytes

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  5. Change From Baseline at Day 28 in Hematology Laboratory Parameters- Erythrocytes

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  6. Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hematocrit

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  7. Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hemoglobin

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  8. Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Alanine Aminotransferase; Alkaline Phosphatase; Aspartate Aminotransferase; Lactate Dehydrogenase

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  9. Change From Baseline at Day 28 in Laboratory Parameters- Albumin; Protein

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  10. Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Bicarbonate; Blood Urea Nitrogen; Calcium; Chloride; Glucose; Magnesium; Phosphate; Potassium; Sodium, Triglyceride

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  11. Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Bilirubin; Creatinine; Direct Bilirubin; Urate

    Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

    Time frame: Baseline and at Day 28

  12. Number of Participants With Manufacturing Success of JCAR017 Product

    Successful product was defined as JCAR017 product was generated and able to be QC released (including nonconforming product) for infusion. Unsuccessful product is defined as no JCAR017 product could be generated after two manufacturing attempts using a single apheresis product for starting material or product was unable to be QC released for infusion.

    Time frame: From screening to JCAR017 infusion (day -35 to day 1)

  13. Overall Response Rate (ORR)

    ORR is defined as the percentage of participants who achieved either a complete response (CR) or complete response with incomplete blood recovery (CRi) on Day 28 that is confirmed on Day 56. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric acute lymphoblastic leukemia (ALL). CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL.

    Time frame: Up to Day 56

  14. Duration of Response (DOR)

    DOR is defined as time from first response (either CR or CRi) until progressive disease (PD), disease relapse, or death from any cause, whichever occurs first. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric ALL. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

    Time frame: From first response (either CR or CRi) until progressive disease (PD), disease relapse, or death from any cause, whichever occurs first (Up to approximately 14 months)

  15. Relapse Free Survival (RFS)

    RFS is defined as time from conforming JCAR017 infusion to the first progressive disease (PD), relapsed disease or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks.

    Time frame: Up to approximately 15 months

  16. Event Free Survival (EFS)

    EFS is defined as time from conforming JCAR017 infusion to progressive disease (PD), relapsed disease, start of a new anticancer therapy including HSCT or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. Only responders are included in he analysis. Censored participants were also analyzed.

    Time frame: From conforming JCAR017 infusion to PD, relapsed disease, start of a new anticancer therapy including Hematopoietic Stem Cell Transplant (HSCT) or death from any cause, whichever occurs first (Up to approximately 15 months)

  17. Overall Survival (OS)

    OS is defined as the interval from the date of first confirming JCAR017 infusion to the date of death due to any reason.

    Time frame: From the date of first confirming JCAR017 infusion to the date of death due to any reason (Up to approximately 24 months)

  18. Minimal Residual Response (MRD) Negative Response Rate

    Minimal Residual Disease (MRD) Negative Response Rate is defined as the percentage of participants achieving either a CR or CRi with a MRD negative bone marrow on Day 28, confirmed on Day 56. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Disease assessments recorded on or after start of a new anticancer therapy, including HSCT, will not be considered, nor will disease assessments reported after a PD or relapse has been observed.

    Time frame: Up to Day 56

  19. Number of Participants Who Achieved a Response After JCAR017 Infusion and Then Proceeded to Hematopoietic Stem Cell Transplant

    Number of participants who undergo HSCT after receiving a JCAR017 infusion and achieving a response are presented. The time of proceeding to HSCT is defined as the time of commencing the conditioning regimen as required for HSCT. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

    Time frame: Up to approximately 24 months

07

Results

Posted Aug 15, 2024
Limitations and caveats
The study was terminated and hence participants were not enrolled in Phase 2 cohorts (r/r B-ALL; MRD+ B-ALL; r/r B-NHL).

Participant flow

Pre-Treatment Period
Participant flow — Pre-Treatment Period
Milestone0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot Assigned
Started9831
Completed8710
Not completed1121
Withdrew: Failure to meet treatment criteria0020
Withdrew: Death0101
Withdrew: Study drug manufacturing failure1000
Lymphodepleting Chemotherapy
Participant flow — Lymphodepleting Chemotherapy
Milestone0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot Assigned
Started8710
Completed7710
Not completed1000
Withdrew: Progressive disease1000
Treatment Period (JCAR017 Infusion)
Participant flow — Treatment Period (JCAR017 Infusion)
Milestone0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot Assigned
Started7710
Completed3610
Not completed4100
Withdrew: Other reason1000
Withdrew: Lost to follow-up0100
Withdrew: Progressive disease1000
Withdrew: Death1000
Withdrew: Study terminated by sponsor1000

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events up to 30 Days Post JCAR017 Infusion

An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 30 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.

Time frame:
From first JCAR017 infusion (Day 1) to 30 days after JCAR017 infusion
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events up to 30 Days Post JCAR017 Infusion
Participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Number of Participants With Treatment Emergent Adverse Events up to 30 Days Post JCAR017 Infusion761
PrimaryNumber of Participants With Dose Limiting Toxicities

A DLT was defined as: * Death not related to disease progression * Grade (Gr) 4 (Life-threatening) neurotoxicity * Gr 3 (Severe) neurotoxicity of greater than 7 days * Gr 3 neurotoxicity does not revert to baseline within 28 days of the start date of the Grade 3 event * Seizures of grade that do not resolve within 7 days * Gr 4 cytokine release syndrome (CRS) that does not resolve to Grade ≤ 3 within 3 days * Gr 3 CRS that does not resolve to Grade ≤ 2 within 7 days * Any increase in aspartate aminotransferase (AST) or ALT \> 3 × ULN and concurrent increase in total bilirubin \> 2 × ULN that is unrelated to CRS and has no other probable reason to explain the combination of increases * Any cardiac, dermatologic, gastrointestinal, hepatic, pulmonary, renal/genitourinary, or neurologic Gr 3 or 4 event not pre-existing or not due to the underlying malignancy * Any other Gr 3 or 4 event deemed unexpected by the Investigator and considered a DLT upon evaluation by the safety review committee

Time frame:
From first JCAR017 infusion (Day 1) to 28 days after JCAR017 infusion
Reported as:
Count of participants · Participants
Number of Participants With Dose Limiting Toxicities
Participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Number of Participants With Dose Limiting Toxicities021
PrimaryConcentration of JCAR017 in Peripheral Blood at Day 28 Post JCAR017 Infusion

Concentration of JCAR017 in Peripheral Blood was assessed by droplet digital polymerase chain reaction.

Time frame:
At day 28 post JCAR017 infusion
Reported as:
Geometric mean · copies per microgram
Concentration of JCAR017 in Peripheral Blood at Day 28 Post JCAR017 Infusion
copies per microgram0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Concentration of JCAR017 in Peripheral Blood at Day 28 Post JCAR017 Infusion1131.821 ± 64.6581457.591 ± 75.5582847.910 ± NA
SecondaryNumber of Participants With Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion

An AE is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater. The following scale for grading was used - Grade 3 = Severe, Grade 4 = Life-Threatening.

Time frame:
From first JCAR017 infusion (Day 1) to 90 days after JCAR017 infusion
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion
Participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
At least one TEAE761
At least one grade 3/4 TEAE651
At Least One TEAE Related To JCAR017551
At Least One grade 3/4 TEAE Related To JCAR017341
SecondaryNumber of Participants With Serious Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion

Serious adverse events (SAE) are defined as any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/ birth defect; constitutes an important medical event. Treatment Emergent Adverse Events (TEAEs) are defined as any AE occurring or worsening on the day of the JCAR017 infusion until 90 days post-treatment (JCAR017 infusion) using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 or greater.

Time frame:
From first JCAR017 infusion (Day 1) to 90 days after JCAR017 infusion
Reported as:
Count of participants · Participants
Number of Participants With Serious Treatment-Emergent Adverse Events up to 90 Days Post JCAR017 Infusion
Participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
AT Least one Serious TEAE531
At Least One Serious TEAE Related To JCAR017131
SecondaryChange From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · 10^9 cells/L
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets
10^9 cells/L0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Basophils0.00 ± 0.025-0.01 ± 0.023-0.01 ± NA
Eosinophils0.03 ± 0.0480.08 ± 0.114-0.08 ± NA
Leukocytes4.01 ± 8.3380.59 ± 1.753-2.00 ± NA
Lymphocytes-0.22 ± 0.8790.27 ± 1.286-0.57 ± NA
Monocytes0.11 ± 0.1630.09 ± 0.173-0.22 ± NA
Neutrophils0.41 ± 0.782-0.18 ± 0.735-1.50 ± NA
Platelets27.33 ± 132.672-68.60 ± 168.583-163.00 ± NA
SecondaryChange From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils/Leukocytes; Eosinophils/Leukocytes; Lymphocytes/Leukocytes; Neutrophils/Leukocytes; Monocytes/Leukocytes

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · Ratio
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Basophils/Leukocytes; Eosinophils/Leukocytes; Lymphocytes/Leukocytes; Neutrophils/Leukocytes; Monocytes/Leukocytes
Ratio0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Basophils/Leukocytes0.25 ± 0.885-0.24 ± 0.654-0.30 ± NA
Eosinophils/Leukocytes0.85 ± 1.4024.28 ± 5.389-2.90 ± NA
Lymphocytes/Leukocytes-29.57 ± 21.690-16.30 ± 25.14033.80 ± NA
Neutrophils/Leukocytes26.45 ± 26.81510.70 ± 18.797-33.90 ± NA
Monocytes/Leukocytes4.35 ± 10.1231.74 ± 4.5150.20 ± NA
SecondaryChange From Baseline at Day 28 in Hematology Laboratory Parameters- Erythrocytes

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · 10^12 cells/L
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Erythrocytes
10^12 cells/L0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Erythrocytes0.04 ± 0.7810.08 ± 0.268-0.70 ± NA
SecondaryChange From Baseline at Day 28 in Hematology Laboratory Parameters- Hematocrit

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · proportion of red blood cells in blood
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hematocrit
proportion of red blood cells in blood0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hematocrit0.00 ± 0.0680.02 ± 0.016-0.03 ± NA
SecondaryChange From Baseline at Day 28 in Hematology Laboratory Parameters- Hemoglobin

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · grams per liter
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hemoglobin
grams per liter0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Change From Baseline at Day 28 in Hematology Laboratory Parameters- Hemoglobin2.33 ± 24.3126.20 ± 6.834-13.00 ± NA
SecondaryChange From Baseline at Day 28 in Chemistry Laboratory Parameters- Alanine Aminotransferase; Alkaline Phosphatase; Aspartate Aminotransferase; Lactate Dehydrogenase

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · units per liter
Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Alanine Aminotransferase; Alkaline Phosphatase; Aspartate Aminotransferase; Lactate Dehydrogenase
units per liter0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Alanine aminotransferase5.33 ± 19.4394.50 ± 16.299-19.00 ± NA
Alkaline phosphatase53.50 ± 158.32278.75 ± 40.950-121.00 ± NA
Aspartate aminotransferase29.17 ± 72.20411.50 ± 13.675-1.00 ± NA
Lactate dehydrogenase992.33 ± 2238.88822.25 ± 43.684-36.00 ± NA
SecondaryChange From Baseline at Day 28 in Laboratory Parameters- Albumin; Protein

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · grams per liter
Change From Baseline at Day 28 in Laboratory Parameters- Albumin; Protein
grams per liter0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Albumin5.83 ± 9.6636.75 ± 2.062-3.00 ± NA
Protein4.00 ± 12.6025.00 ± 6.683-6.00 ± NA
SecondaryChange From Baseline at Day 28 in Chemistry Laboratory Parameters- Bicarbonate; Blood Urea Nitrogen; Calcium; Chloride; Glucose; Magnesium; Phosphate; Potassium; Sodium, Triglyceride

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · mmol/L
Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Bicarbonate; Blood Urea Nitrogen; Calcium; Chloride; Glucose; Magnesium; Phosphate; Potassium; Sodium, Triglyceride
mmol/L0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Bicarbonate2.53 ± 4.453-2.65 ± 1.9194.10 ± NA
Blood Urea Nitrogen3.60 ± 3.5422.43 ± 0.8260.20 ± NA
Calcium0.13 ± 0.1570.04 ± 0.058-0.17 ± NA
Chloride-1.50 ± 4.3241.50 ± 1.2911.00 ± NA
Glucose0.32 ± 0.641-0.08 ± 0.47214.90 ± NA
Magnesium0.06 ± 0.1070.06 ± 0.1090.00 ± NA
Phosphate0.02 ± 0.281-0.02 ± 0.336-0.16 ± NA
Potassium-0.05 ± 0.6720.20 ± 0.5351.50 ± NA
Sodium1.00 ± 2.6082.25 ± 2.2172.00 ± NA
Triglyceride0.45 ± 1.6520.29 ± 0.3200.33 ± NA
SecondaryChange From Baseline at Day 28 in Chemistry Laboratory Parameters- Bilirubin; Creatinine; Direct Bilirubin; Urate

Baseline is defined as the last assessment with non-missing value on or prior to the first date of the lymphodepletion chemotherapy.

Time frame:
Baseline and at Day 28
Reported as:
Mean · umol/L
Change From Baseline at Day 28 in Chemistry Laboratory Parameters- Bilirubin; Creatinine; Direct Bilirubin; Urate
umol/L0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Bilirubin20.26 ± 41.498-1.00 ± 6.9282.00 ± NA
Creatinine9.84 ± 14.2181.50 ± 9.000-2.00 ± NA
Direct Bilirubin13.44 ± 33.601-0.25 ± 0.5000.00 ± NA
Urate43.51 ± 94.08185.00 ± 71.6159.00 ± NA
SecondaryNumber of Participants With Manufacturing Success of JCAR017 Product

Successful product was defined as JCAR017 product was generated and able to be QC released (including nonconforming product) for infusion. Unsuccessful product is defined as no JCAR017 product could be generated after two manufacturing attempts using a single apheresis product for starting material or product was unable to be QC released for infusion.

Time frame:
From screening to JCAR017 infusion (day -35 to day 1)
Reported as:
Count of participants · Participants
Number of Participants With Manufacturing Success of JCAR017 Product
Participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot Assigned
Number of Participants With Manufacturing Success of JCAR017 Product7721
SecondaryOverall Response Rate (ORR)

ORR is defined as the percentage of participants who achieved either a complete response (CR) or complete response with incomplete blood recovery (CRi) on Day 28 that is confirmed on Day 56. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric acute lymphoblastic leukemia (ALL). CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL.

Time frame:
Up to Day 56
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Overall Response Rate (ORR)50.0 (11.8 to 88.2)25.0 (0.6 to 80.6)100.0 (2.5 to 100.0)
SecondaryDuration of Response (DOR)

DOR is defined as time from first response (either CR or CRi) until progressive disease (PD), disease relapse, or death from any cause, whichever occurs first. Response assessment was performed according to the 2019 Comprehensive Cancer Network (NCCN) response criteria guidelines for pediatric ALL. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

Time frame:
From first response (either CR or CRi) until progressive disease (PD), disease relapse, or death from any cause, whichever occurs first (Up to approximately 14 months)
Reported as:
Median · months
Duration of Response (DOR)
months0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Duration of Response (DOR)13.70 (2.46 to 13.70)NA (4.93 to 4.93)NA (2.23 to 2.23)
SecondaryRelapse Free Survival (RFS)

RFS is defined as time from conforming JCAR017 infusion to the first progressive disease (PD), relapsed disease or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks.

Time frame:
Up to approximately 15 months
Reported as:
Median · months
Relapse Free Survival (RFS)
months0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Relapse Free Survival (RFS)7.77 (0.46 to 14.62)6.98 (1.15 to 8.97)NA (3.12 to 3.12)
SecondaryEvent Free Survival (EFS)

EFS is defined as time from conforming JCAR017 infusion to progressive disease (PD), relapsed disease, start of a new anticancer therapy including HSCT or death from any cause, whichever occurs first. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Relapsed disease is defined as Reappearance of blasts in the blood or bone marrow (\> 5%) or \> 1% with previous/supportive molecular findings or in any extramedullary site after a CR. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. Only responders are included in he analysis. Censored participants were also analyzed.

Time frame:
From conforming JCAR017 infusion to PD, relapsed disease, start of a new anticancer therapy including Hematopoietic Stem Cell Transplant (HSCT) or death from any cause, whichever occurs first (Up to approximately 15 months)
Reported as:
Median · months
Event Free Survival (EFS)
months0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Event Free Survival (EFS)3.24 (0.46 to 14.62)5.42 (1.15 to 8.97)3.12 (3.12 to 3.12)
SecondaryOverall Survival (OS)

OS is defined as the interval from the date of first confirming JCAR017 infusion to the date of death due to any reason.

Time frame:
From the date of first confirming JCAR017 infusion to the date of death due to any reason (Up to approximately 24 months)
Reported as:
Median · months
Overall Survival (OS)
months0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Overall Survival (OS)7.13 (0.76 to NA)7.08 (4.99 to NA)8.90 (NA to NA)
SecondaryMinimal Residual Response (MRD) Negative Response Rate

Minimal Residual Disease (MRD) Negative Response Rate is defined as the percentage of participants achieving either a CR or CRi with a MRD negative bone marrow on Day 28, confirmed on Day 56. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease. Disease assessments recorded on or after start of a new anticancer therapy, including HSCT, will not be considered, nor will disease assessments reported after a PD or relapse has been observed.

Time frame:
Up to Day 56
Reported as:
Number · percentage of participants
Minimal Residual Response (MRD) Negative Response Rate
percentage of participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Minimal Residual Response (MRD) Negative Response Rate16.7 (0.4 to 64.1)25.0 (0.6 to 80.6)100.0 (2.5 to 100.0)
SecondaryNumber of Participants Who Achieved a Response After JCAR017 Infusion and Then Proceeded to Hematopoietic Stem Cell Transplant

Number of participants who undergo HSCT after receiving a JCAR017 infusion and achieving a response are presented. The time of proceeding to HSCT is defined as the time of commencing the conditioning regimen as required for HSCT. CR is defined as absence of circulating blasts, extramedullary disease, lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement, Trilineage hematopoiesis (TLH) and \< 5%, Absolute neutrophil count (ANC) \> 1000 per microliter, Platelets \> 100,000 per microliter and no recurrence for 4 weeks. CRi is defined as meeting all criteria for CR except platelets \< 100,000/μL or ANC is \< 1000/μL. Disease progression is defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.

Time frame:
Up to approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Achieved a Response After JCAR017 Infusion and Then Proceeded to Hematopoietic Stem Cell Transplant
Participants0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kg
Number of Participants Who Achieved a Response After JCAR017 Infusion and Then Proceeded to Hematopoietic Stem Cell Transplant111

Adverse events

Collected over All-cause mortality was collected from JCAR017 infusion until their study completion (up to approximately 1928 days). Serious and non-serious adverse events were collected from first JCAR017 infusion (Day 1) to 90 days post JCAR017 infusion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.05 x 10^6 CAR+ T Cells/kg6/9 (66.7%)5/7 (71.4%)7/7 (100%)
0.15 x 10^6 CAR+ T Cells/kg4/8 (50%)3/6 (50%)6/6 (100%)
0.50 x 106 CAR+T Cells/kg1/3 (33.3%)1/1 (100%)1/1 (100%)
Not Assigned1/1 (100%)——
Most frequent serious events
Most frequent serious events
Event0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot Assigned
Brain oedemaNervous system disorders0/70/61/1—
NeurotoxicityNervous system disorders1/71/61/1—
Cytokine release syndromeImmune system disorders0/73/60/1—
Infusion related reactionInjury, poisoning and procedural complications0/71/60/1—
PneumoniaInfections and infestations1/70/60/1—
SepsisInfections and infestations1/70/60/1—
ViraemiaInfections and infestations1/70/60/1—
Extradural haematomaInjury, poisoning and procedural complications1/70/60/1—
Most frequent other events
Showing 10 of 78
Most frequent other events
Event0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot Assigned
AnaemiaBlood and lymphatic system disorders5/75/61/1—
CoagulopathyBlood and lymphatic system disorders0/70/61/1—
LeukopeniaBlood and lymphatic system disorders4/71/61/1—
NeutropeniaBlood and lymphatic system disorders3/72/61/1—
ThrombocytopeniaBlood and lymphatic system disorders4/73/61/1—
BradycardiaCardiac disorders0/71/61/1—
TachycardiaCardiac disorders0/70/61/1—
DiarrhoeaGastrointestinal disorders0/71/61/1—
Cytokine release syndromeImmune system disorders4/71/61/1—
HypogammaglobulinaemiaImmune system disorders1/71/61/1—

Baseline characteristics

Age, Customized
Age, Customized(participants)0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot AssignedTotal
< 6 years34209
>= 6 to < 12 years53109
>= 12 to < 18 years11013
Sex: Female, Male
Sex: Female, Male(Participants)0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot AssignedTotal
Female542011
Male441110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot AssignedTotal
Hispanic or Latino43119
Not Hispanic or Latino442010
Unknown or Not Reported11002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.05 x 10^6 CAR+ T Cells/kg0.15 x 10^6 CAR+ T Cells/kg0.50 x 106 CAR+T Cells/kgNot AssignedTotal
American Indian or Alaska Native11013
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White653014
More than one race00000
Unknown or Not Reported22004
08

Study locations

19 sites
  • Local Institution - 163
    Duarte, California 91010, United States
  • Local Institution - 167
    Redwood City, California 94063, United States
  • Local Institution - 166
    Saint Petersburg, Florida 33701, United States
  • Local Institution - 160
    New York, New York 10021, United States
  • Local Institution - 162
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 164
    Dallas, Texas 75390-7208, United States
  • Local Institution - 165
    Houston, Texas 77030, United States
  • Local Institution - 161
    Seattle, Washington 98105, United States
  • Local Institution - 168
    Wauwatosa, Wisconsin 53226, United States
  • Local Institution - 601
    Lyon, 69008, France
  • Local Institution - 602
    Marseille Cedex 01, 13005, France
  • Local Institution - 600
    Paris, 75935, France
  • Local Institution - 501
    Berlin, 13353, Germany
  • Local Institution - 500
    Frankfurt, D-60590, Germany
  • Local Institution - 301
    Monza, 20900, Italy
  • Local Institution - 300
    Roma, 00165, Italy
  • Local Institution - 400
    Utrecht, 3584 CS, Netherlands
  • Local Institution - 251
    Esplugues de Llobregat, 08950, Spain
  • Local Institution - 250
    Madrid, 28009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jan 2024, 63 months.

Results were first posted in Aug 2024, 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2018
First posted
Nov 16, 2018
StartActual
Oct 17, 2018
Primary completionActual
Jan 26, 2024
CompletionActual
Jan 26, 2024
Results first posted
Aug 15, 2024
Last update
Aug 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03743246
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 16, 2018
Start date
Oct 17, 2018
Primary completion
Jan 26, 2024
Completion
Jan 26, 2024
Results posted
Aug 15, 2024
Last update
Aug 15, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisocabtagene maraleucel

Start the discussion